All AbMole products are for research use only, cannot be used for human consumption.
SU11274 (PKI-SU11274) is a Met kinase inhibitor with IC50 of 10 nM. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. c-Met protein was activated in all cell lines, and SU11274 can block proliferation (and colony formation). c-Met inhibition could significantly suppress cell survival and proliferation as well as enhance the radiosensitivity of DU145 cells. SU11274 on DU145 cells may include the inhibition of c-Met signaling, depolarization of the mitochondrial membrane potential, impairment of DNA repair function, abrogation of cell cycle arrest, and enhancement of cell death.
 |
Source | Oncol Lett (2015). Figure 5.SU11274 |
| Method | Scratch assay | |
| Cell Lines | PK-45H cells | |
| Concentrations | 30 μM | |
| Incubation Time | 48 h | |
| Results | Following treatment with 30 μM SU11274, cell motility was suppressed to 1.0±0.3% in MIA‑Paca2 cells (P<0.05) and 14.7±3.5% in PK‑45H cells (P<0.05) of the level of cells treated with 0 μM SU11274, respectively. |
| Cell Experiment | |
|---|---|
| Cell lines | LoVo cells line |
| Preparation method | MTT assay. After pancreatic enzymeization, cells were seeded in 96-well plates at 1 9 105/ml (200 ll/well) and allowed to adhere overnight. SU11274, dissolved in 1 % DMSO and diluted in medium, was added at different concentrations 0.1, 0.5, 2.5 μM, 2μl per well. Another 4 wells were set as a reference and incubated for 24, 48 and 72 h. Twenty microliter MTT (5 g/l; Invitrogen, USA) was added, and cells were incubated for another 4 h. The supernatant was removed, 150 ll DMSO was added and oscillated for 10 min avoiding light at room temperature. The assessment procedure was repeated 3 times, and the average value was determined from each well as the absorbance value at 490 nm on a microplate reader. |
| Concentrations | 0.1, 0.5, 2.5 μM |
| Incubation time | 24, 48 and 72 h |
| Animal Experiment | |
|---|---|
| Animal models | LoVo cells tumor xenograft in 4- to 5-week-old female nude mice (BALB/c-nu/nu) |
| Formulation | 1 % DMSO |
| Dosages | 0.18, 0.09, 0.0225 mg/kg once daily for 30 days from the day that the tumors became palpable |
| Administration | celiac injection |
| Molecular Weight | 568.09 |
| Formula | C28H30ClN5O4S |
| CAS Number | 658084-23-2 |
| Solubility (25°C) | DMSO 82 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related c-Met Products |
|---|
| AMG-208
AMG-208 is a potent small molecular inhibitor c-Met with an IC50 of 9.3 nM. AMG-208 is also a CYP3A4 inhibitor with an IC50 of 32 μM. AMG-208 has anti-cancer activity. |
| BMS-777607
BMS-777607 is a selective and potent small-molecule met kinase inhibitor for c-Met, Axl, Ron and Tyro3 with IC50s of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM, respectively. |
| BMS 794833
BMS-794833 is a potent ATP competitive Met/VEGFR-2 kinase inhibitor. |
| AMG-458
AMG-458 is a potent, selective and orally bioavailable c-Met inhibitor, with Ki values of 1.2 nM and 2.0 nM for human and mouse c-Met, respectively. |
| XL-184
Cabozantinib (XL184, BMS-907351) is a small molecule inhibits multiple receptor tyrosine kinases, specifically MET and VEGFR2 with IC50 values of 0.035 and 1.8 nM for VEGFR2 and Met respectively. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
